DYAI · XBRL financial data

Dyadic International financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (DYAI's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	1,602	2,404	2,930	2,899	3,495	3,090
Cost of goods and services sold	1,425	1,944	2,123	1,976	1,195	2,320
Research and development	3,868	8,392	4,501	3,297	2,044	2,155
General and administrative	6,085	6,698	6,422	5,817	6,135	5,762
Operating income (loss)	(10,026)	(14,727)	(10,166)	(8,230)	(5,901)	(7,193)
Interest income	—	—	—	—	457	284
Other income (expense)	—	1,606	250	0	—	—
Income tax expense (benefit)	31	0	—	—	—	—
Net income (loss)	(9,325)	(13,070)	(9,735)	(6,795)	(5,809)	(7,365)
Earnings per share, basic USD per share	—	(0.47)	(0.34)	(0.24)	(0.20)	(0.23)
Earnings per share, diluted USD per share	—	—	—	—	(0.20)	(0.23)
Weighted average shares, basic thousands of shares	—	—	28,364	28,799	—	—
Weighted average shares, diluted thousands of shares	—	—	—	—	29,318	32,624

Fiscal years (DYAI's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	20,637	15,748	5,794	6,515	6,507	4,622
Short-term investments	—	—	—	—	2,781	2,699
Accounts receivable	294	278	330	466	237	1,090
Prepaid and other current assets	281	376	392	328	303	219
Total current assets	29,781	21,008	13,422	8,067	9,828	9,897
Right-of-use asset	—	—	0	141	92	39
Total assets	30,072	21,299	13,713	8,219	9,930	9,946
Accounts payable	1,013	1,548	1,276	656	482	852
Accrued liabilities	490	710	955	1,057	970	968
Total current liabilities	1,626	2,556	2,449	2,252	2,448	3,687
Lease liability, non-current	—	—	0	89	35	—
Total liabilities	1,626	2,909	2,625	2,341	7,460	8,713
Accumulated deficit	(50,676)	(63,747)	(73,482)	(80,277)	(86,086)	(93,451)
Total stockholders' equity	28,447	18,390	11,088	5,879	2,470	1,232
Total liabilities and equity	30,072	21,299	13,713	8,219	9,930	9,946
Common shares outstanding (cover page) thousands of shares	27,554	28,264	28,811	28,974	30,091	36,439

Fiscal years (DYAI's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(9,325)	(13,070)	(9,735)	(6,795)	(5,809)	(7,365)
Stock-based compensation	1,652	1,784	1,889	1,244	1,126	930
Net cash from operating activities	(6,574)	(11,277)	(8,084)	(6,727)	(3,975)	(5,702)
Net cash from investing activities	22,122	5,222	(2,369)	7,450	(1,876)	82
Net cash from financing activities	255	1,230	544	0	5,849	4,965
Net change in cash	15,814	(4,889)	(9,954)	721	(8)	(653)

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Dyadic International	1,425	961	(1,818)*	36.4M	1.7 quarters	Q2 FY26 10-QJun 30, 2026
Aytu Biopharma	26,308	16,106*	4,406*	10.9M	—	Q4 FY26 10-KJun 30, 2026
Kala Bio	229	not reported	(1,535)*	19.3M	4.7 quarters	Q2 FY26 10-QJun 30, 2026
Lexaria Bioscience	3,500	0	(1,635)*	24.8M	2.2 quarters	Q3 FY26 10-QMay 31, 2026
Tenax Therapeutics	118,000	0*	(14,150)*	37.4M	8.3 quarters	Q2 FY26 10-QJun 30, 2026
Nanoviricides	2,794	not reported	(2,122)*	25.5M	1.3 quarters	Q4 FY26 10-KJun 30, 2026
Curis	5,073	0	(9,646)*	2.1M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Lisata Therapeutics	10,443	0	(2,649)*	9.0M	3.9 quarters	Q2 FY26 10-QJun 30, 2026
Pulmatrix	2,168	not reported	(1,106)*	3.7M	2.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.